Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer
International Journal of Experimental Pathology Jan 11, 2018
Pugongchai A, et al. - SOX11 promoter methylation was studied in prostate adenocarcinomas by comparison with benign prostatic hyperplasia (BPH), presuming that hypermethylation may be responsible for SOX11 silencing in human prostate cancer. SOX11 is promising as a methylation marker candidate for differential diagnosis and risk stratification for prostate cancer.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
